<DOC>
	<DOC>NCT00346242</DOC>
	<brief_summary>The evaluation of efficacy is performed by laboratory monitoring of bone density and resorption markers and clinical monitoring of bone density improvement. This is a prospective, randomized, parallel group, single blind study of one year treatment with zoledronic acid every 6 months as compared to one year treatment with zoledronic acid every 3 months and to placebo every 3 months in patients with hemoglobin syndromes and risk of skeletal complications.</brief_summary>
	<brief_title>Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients with thalassaemia or sickle cell anaemia and bone density, zscores &lt; 1.5, in at least one of the examined sites Normal renal function. Urea and creatinine should not exceed &gt; 2fold the upper limit of normal (&lt; 2 x ULN). Other protocoldefined inclusion / exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>thalassemia</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>skeletal events</keyword>
</DOC>